WO2010119455A3 - Composition pharmaceutique injectable à libération prolongée - Google Patents
Composition pharmaceutique injectable à libération prolongée Download PDFInfo
- Publication number
- WO2010119455A3 WO2010119455A3 PCT/IN2010/000243 IN2010000243W WO2010119455A3 WO 2010119455 A3 WO2010119455 A3 WO 2010119455A3 IN 2010000243 W IN2010000243 W IN 2010000243W WO 2010119455 A3 WO2010119455 A3 WO 2010119455A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- pharmaceutical composition
- sustained release
- release pharmaceutical
- injectable sustained
- injectable
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/541—Organic ions forming an ion pair complex with the pharmacologically or therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/554—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being a steroid plant sterol, glycyrrhetic acid, enoxolone or bile acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
- A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Botany (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Hydrogenated Pyridines (AREA)
Abstract
La présente invention concerne une composition pharmaceutique injectable comprenant des agents antipsychotiques ayant des groupes basiques.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IN978/MUM/2009 | 2009-04-15 | ||
IN978MU2009 | 2009-04-15 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2010119455A2 WO2010119455A2 (fr) | 2010-10-21 |
WO2010119455A3 true WO2010119455A3 (fr) | 2011-01-27 |
Family
ID=42982942
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/IN2010/000243 WO2010119455A2 (fr) | 2009-04-15 | 2010-04-15 | Composition pharmaceutique injectable à libération prolongée |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2010119455A2 (fr) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010118435A2 (fr) * | 2009-04-10 | 2010-10-14 | Tufts Medical Center, Inc. | Activation de par-1 par la métalloprotéinase-1 (mmp-1) |
KR102013476B1 (ko) * | 2012-07-26 | 2019-08-22 | 히사미쓰 세이야꾸 가부시키가이샤 | 첩부제 및 그 제조 방법 |
WO2016023658A1 (fr) * | 2014-08-14 | 2016-02-18 | Alrise Biosystems Gmbh | Formulations injectables d'asénapine |
CA2987081C (fr) * | 2015-06-11 | 2022-08-30 | Alrise Biosystems Gmbh | Procede pour la preparation de microparticules chargees de medicament |
CN104940150B (zh) * | 2015-06-16 | 2020-11-20 | 黑龙江大学 | 一种帕利哌酮缓释微球注射剂的制备方法 |
EP3558276A1 (fr) | 2016-12-20 | 2019-10-30 | LTS Lohmann Therapie-Systeme AG | Système thérapeutique transdermique contenant de l'asénapine et un polysiloxane ou un polyisobutylène |
MX2019007391A (es) | 2016-12-20 | 2019-08-16 | Lts Lohmann Therapie Systeme Ag | Sistema terapeutico transdermico que contiene asenapina. |
WO2019002204A1 (fr) | 2017-06-26 | 2019-01-03 | Lts Lohmann Therapie-Systeme Ag | Système thérapeutique transdermique contenant de l'asénapine et un polymère hybride acrylique de type silicone |
WO2019243452A1 (fr) | 2018-06-20 | 2019-12-26 | Lts Lohmann Therapie-Systeme Ag | Système thérapeutique transdermique contenant de l'asénapine |
WO2020091845A1 (fr) * | 2018-10-29 | 2020-05-07 | University Of South Florida | Compositions de lithium-cholestérol et procédés de traitement de la maladie d'alzheimer et de troubles neurologiques |
EP4319721A1 (fr) * | 2021-04-07 | 2024-02-14 | Proneurogen, Inc. | Formulations de gel injectables à libération prolongée contenant des oligopeptides de l'angiotensine-(1-7) ou des variants de ceux-ci |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20020132007A1 (en) * | 1998-03-18 | 2002-09-19 | University Technology Corporation | Sustainded-release composition including amorphous polymer |
WO2005032523A1 (fr) * | 2003-09-30 | 2005-04-14 | Acusphere, Inc. | Formulations pharmaceutiques a effet prolonge, administrees par injection, par voie orale ou topique |
-
2010
- 2010-04-15 WO PCT/IN2010/000243 patent/WO2010119455A2/fr active Application Filing
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20020132007A1 (en) * | 1998-03-18 | 2002-09-19 | University Technology Corporation | Sustainded-release composition including amorphous polymer |
WO2005032523A1 (fr) * | 2003-09-30 | 2005-04-14 | Acusphere, Inc. | Formulations pharmaceutiques a effet prolonge, administrees par injection, par voie orale ou topique |
Also Published As
Publication number | Publication date |
---|---|
WO2010119455A2 (fr) | 2010-10-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2010119455A3 (fr) | Composition pharmaceutique injectable à libération prolongée | |
EP2240022A4 (fr) | Compositions pharmaceutiques | |
GB0814695D0 (en) | Pharmaceutical compositions | |
IL228817A0 (en) | Pharmaceutical compounds | |
EP2373681A4 (fr) | Compositions pharmaceutiques | |
WO2012042371A3 (fr) | Composition pharmaceutique | |
AP2010005380A0 (en) | Extracellular matrix compositions. | |
PL2323623T3 (pl) | Kompozycje farmaceutyczne | |
ZA201109138B (en) | Pharmaceutical composition having improved solubility | |
ZA201102715B (en) | Solid pharmaceutical composition | |
IL208387A0 (en) | Pharmaceutical composition | |
ZA201100871B (en) | Solid pharmaceutical composition | |
ZA201006224B (en) | Pharmaceutical composition | |
PL2405753T3 (pl) | Kompozycja repelentu przeciwko owadom | |
UA96476C2 (ru) | Фармацевтические композиции, которые содержат ирбесартан | |
ZA201100529B (en) | Solid pharmaceutical composition comprising exemestane | |
GB2464200B (en) | Pharmaceutical composition | |
IL206487A0 (en) | Pharmaceutical compositions | |
EP2311493A4 (fr) | Composition cytotoxique | |
GB0817969D0 (en) | Pharmaceutical composition | |
HK1182939A1 (en) | Stable pharmaceutical composition | |
GB0800659D0 (en) | Pharmaceutical Compositions | |
EP2327671A4 (fr) | Compositions accélérant le temps de prise de ciments | |
AU2008902603A0 (en) | Injectable Formulations | |
IL199679A0 (en) | Injectable pharmaceutical composition |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 10764178 Country of ref document: EP Kind code of ref document: A2 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 10764178 Country of ref document: EP Kind code of ref document: A2 |